Eckert & Ziegler BEBIG GmbH and TCL Healthcare Equipment (Shanghai) Co., Ltd signed a joint venture agreement to enter the High Dose Rate Brachytherapy solutions market in China.

The parties will develop, manufacture and distribute an HDR afterloader for the Chinese market. The joint venture will trade under the name TCL Eckert & Ziegler BEBIG Healthcare (Wuxi) Co. Ltd. and is owned 51% by TCL Healthcare Equipment (Shanghai) Co., Ltd. and 49% by Eckert & Ziegler BEBIG GmbH.

TCL Healthcare Equipment (Shanghai) Co., Ltd. is part of the TCL Healthcare Group (a listed Chinese company) and Eckert & Ziegler BEBIG GmbH is part of Eckert & Ziegler AG.

http://sea.tclmedical.com/gongsixinwen/20190801159.html 

About TCL Healthcare Equipment (Shanghai) Co., Ltd. (TCL Healthcare Equipment)

TCL Healthcare Group, established in 2009, is one of the leading suppliers of healthcare diagnostic imaging products in China and a provider of  third-party imaging services.

About Eckert & Ziegler BEBIG GmbH (Eckert & Ziegler BEBIG)

Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treatment of cancer using brachytherapy. The company headquarters are in Germany, with production facilities in Germany and in the USA, as well as offices throughout Europe, Asia and the USA. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company’s products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.

Buchang held its 2017 Annual Shareholder Meeting in June 2018, where it approved the payment of its FY2017 dividend and announced a bonus share issue. Details of these are set out below:

– Dividend: FY2017 profit distribution plan of RMB1.614 per share (before tax)
– Bonus Share: the issuance of 3 new shares for every 10 existing shares held

In addition, the Company also finalised its FY2018 budget as follows:

– revenue of RMB16.2 billion (a 16.8% increase Y-o-Y), and
– net profit of RMB1.8 billion (a 9.8% increase Y-o-Y)

About Buchang

Buchang Pharmaceuticals is one of the leading traditional Chinese medicine (TCM) companies in China. Buchang was founded in 1993 by Mr. Zhao Buchang and his eldest son, Mr. Zhao Tao. Starting as a small TCM drug manufacturer, Buchang has evolved into a sales and marketing powerhouse. The Company has the most extensive sales network amongst its peers in China, covering over 15,000 hospitals and 150,000 drug stores. The Company’s product portfolio consists of in-house developed products, as well as products that it acquired and turned into blockbusters. Buchang’s brand name is widely recognized by physicians and patients throughout China.

Buchang held its 2016 Annual Shareholder Meeting in May 2017, where it approved the payment of its FY2016 dividend. The Company will distribute a total cash dividend of RMB 1.1 billion, or RMB 16.14 for every 10 shares held (before tax). The dividend is expected to be distributed in July 2017.

About Buchang

Buchang Pharmaceuticals is one of the leading traditional Chinese medicine (TCM) companies in China. Buchang was founded in 1993 by Mr. Zhao Buchang and his eldest son, Mr. Zhao Tao. Starting as a small TCM drug manufacturer, Buchang has evolved into a sales and marketing powerhouse. The Company has the most extensive sales network amongst its peers in China, covering over 15,000 hospitals and 150,000 drug stores. The Company’s product portfolio consists of in-house developed products, as well as products that it acquired and turned into blockbusters. Buchang’s brand name is widely recognized by physicians and patients throughout China.

Dongcheng, a pharmaceutical company listed on the A-share market (SZSE:002675), signed an agreement  to acquire 100% of the outstanding shares of AMS in May 2017. The transaction values AMS at a valuation of RMB1.6 billion, which is equivalent to a FY2016 P/E multiple of 24.4x.

According to the agreement, SKR expects to receive a cash payment for 50% of its shareholding on completion of the transaction based on a valuation of RMB1.6 billion, and an additional cash payment for the remaining 50% shareholding at the fair market valuation of AMS based on FY2019’s audited financial statements.

About AMS

Advanced Medical Systems Limited provides radiopharmaceuticals to hospitals and imaging centres for use in Positron Emission Tomography (“PET”) scanners and Positron Emission Tomography / Computed Tomography (“PET/CT”) scanners. The Company is the #1 player in China in the positron radiopharmaceutical industry and one of only two companies licensed to produce and sell Fluorodeoxy- glucose (F18-FDG), which is used in PET/CT scanners. AMS also distributes cyclotrons and provides maintenance services for nuclear medicine equipment.

We are delighted to announce that Buchang completed its A-share IPO on 18 November 2016. The Company listed on the main board of the Shanghai Stock Exchange under the ticker symbol 603858. A link to the news story on the Company’s website can be found here and a link to Buchang’s share price quote can be found here (Bloomberg).

About Buchang Pharmaceuticals

Buchang Pharmaceuticals is one of the leading traditional Chinese medicine (TCM) companies in China. Buchang was founded in 1993 by Mr. Zhao Buchang and his eldest son, Mr. Zhao Tao. Starting as a small TCM drug manufacturer, Buchang has evolved into a sales and marketing powerhouse. The Company has the most extensive sales network amongst its peers in China, covering over 15,000 hospitals and 150,000 drug stores. The Company’s product portfolio consists of in-house developed products, as well as products that it acquired and turned into blockbusters. Buchang’s brand name is widely recognized by physicians and patients throughout China.

We are very happy to report that Buchang Pharmaceuticals, China’s leading private traditional Chinese medicine company and a HAO II portfolio company, received listing approval from the China Securities Regulatory Commission (“CSRC”) on 13 July for its planned A-share IPO.

A link to the announcement on the CSRC’s website (in Chinese) can be found here.